Heart And Vascular – Johns Hopkins Medicine Podcasts

A large number of people who could benefit from medicines to reduce cholesterol and consequent cardiovascular risk aren’t taking them, a study by Caleb Alexander, a drug efficacy expert at Johns Hopkins, and colleagues has shown. Alexander says this has …

Many people who could benefit from medicines to reduce their cardiovascular risk aren’t getting them, Elizabeth Tracey reports Read More »

Among people who’ve had a heart attack, stroke, or other cardiovascular event and need a cholesterol lowering medicine, about 2/3 will take one. Among those who have not had such an event but do have high cholesterol only about a …

Engaging both patients and physicians in the use of cholesterol lowering medicines is needed, Elizabeth Tracey reports Read More »

Only about 25 percent of people who need cholesterol lowering medicines based on blood tests take them,  with about 2/3 of those who’ve had a cardiovascular event doing so, a study by Caleb Alexander, a drug safety and efficacy expert at …

Why don’t people who are eligible for cholesterol lowering medicines take them? Elizabeth Tracey reports Read More »

Not taking medicines to lower cholesterol when you clearly need them increases your risk for heart attacks, strokes and other cardiovascular events. Yet a study by Caleb Alexander, a drug safety and efficacy expert at Johns Hopkins, and colleagues, shows …

Just how much does it cost our healthcare system when people don’t take needed medicines to reduce cardiovascular risk? Elizabeth Tracey reports Read More »

Cardiovascular disease, including heart attacks and strokes, remains the number one cause of death in the United States, yet many people who should be taking medicines to lower their risk by lowering cholesterol aren’t. That’s according to a study by …

The gap between recommendations and who is actually taking medicines to lower cardiovascular disease risk is huge, Elizabeth Tracey reports Read More »

Most people have heard of statins, drugs that lower cholesterol and consequent cardiovascular disease risk. Caleb Alexander, a drug safety and efficacy expert at Johns Hopkins, and colleagues, have looked at just how many people who should be taking such …

How many people aren’t taking needed medicines to reduce cardiovascular risk? Elizabeth Tracey reports Read More »

A new advisory from the American Heart Association makes it clear: your risk for dying of heart disease is inextricably linked to the health of your metabolism and your kidneys. Chiadi Ndumele, a Johns Hopkins cardiologist and head of the …

Can you reverse your risk for cardiovascular kidney metabolic syndrome? Elizabeth Tracey reports Read More »

CKM stands for cardiovascular kidney metabolic syndrome, and Chiadi Ndumele, a Johns Hopkins cardiologist and chair of the American Heart Association writing committee that described the syndrome, says while people’s choices determine much of their risk to develop it, it’s …

Risk for cardiovascular kidney metabolic syndrome is linked to behavior, Elizabeth Tracey reports Read More »

Cardiovascular kidney metabolic syndrome, or CKM, is a holistic approach to integrating a number of conditions that work together to negatively impact health and longevity. That’s according to Chiadi Ndumele, a cardiologist at Johns Hopkins and head of the writing …

Just how big a risk is CKM syndrome? Elizabeth Tracey reports Read More »

CKM syndrome, which stands for cardiovascular kidney metabolic syndrome, has just been described by the American Heart Association as something clinicians need to evaluate in their patients with conditions like obesity and diabetes. Chiadi Ndumele, chair of the heart association’s …

Existing therapies may help with cardiovascular kidney metabolic syndrome, Elizabeth Tracey reports Read More »